Evidence map›Paper›PMID 35264382›Full record

ArticleBMJ case reports2022

Non-specificity of symptoms in infantile-onset Pompe disease may delay the diagnosis and institution of treatment.

Udara Dilrukshi Senarathne, Eresha Jasinge, Sarojini Viknarajah Mohan, Samantha Waidyanatha

Open access · hybridAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Udara Dilrukshi SenarathneDepartment of Biochemistry, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka udara.senarathne@sjp.ac.lk.ORCID http://orcid.org/0000-0003-2329-6871
Eresha JasingeDepartment of Chemical Pathology, Lady Ridgeway Hospital for Children, Borella, Sri Lanka.
Sarojini Viknarajah MohanPaediatric Unit, Lady Ridgeway Hospital for Children, Borella, Western, Sri Lanka.
Samantha WaidyanathaPaediatric Unit, Lady Ridgeway Hospital for Children, Borella, Western, Sri Lanka.
Lady Ridgeway Hospital for Children · LKUniversity of Sri Jayewardenepura · LK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pompe disease is an autosomal-recessive inherited disorder of glycogen metabolism due to lysosomal acid alpha-glucosidase deficiency. The infantile-onset form is rapidly fatal if left untreated and presents with respiratory symptoms, a typical encounter during infancy. We discuss two infants presenting with respiratory symptoms since early infancy and found to have cardiomegaly, hypotonia, elevated muscle enzymes, leading to the diagnosis of Pompe disease with genetic confirmation. However, both infants expired before the enzyme replacement therapy due to complications of irreversible muscle damage despite supportive medical care. Presentation with respiratory symptoms common during childhood, absence of alarming symptoms such as hypoglycaemia, ketoacidosis or encephalopathy, and relative rarity of Pompe disease can contribute to lapses in the early diagnosis as observed in the index patients. Thus, these cases emphasise the importance of vigilant assessment of common paediatric presentations, which may be presenting symptoms of underlying sinister pathologies.

Indexed as

Glycogen Storage Disease Type IIalpha-GlucosidasesCardiomegalyChildEnzyme Replacement TherapyHumansInfantMuscle Hypotoniaalpha-Glucosidasescongenital disordersgenetic screening / counsellingpathology

Identifiers

PMID35264382
PMCPMC8915381
OpenAlexW4220874618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.